Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. announced the approval of a phase 2 clinical trial for HLX79 injection in combination with HANLIKANG for treating active glomerulonephritis. This development marks a significant step in the company’s efforts to enhance treatment options for autoimmune diseases. The combination therapy is expected to improve B lymphocyte depletion, offering potential benefits to patients with glomerulonephritis. As no similar combination has been approved globally, this positions Shanghai Henlius Biotech as a pioneer in this therapeutic area, potentially impacting its market positioning and offering new hope for stakeholders.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of biologic drugs. The company is involved in creating innovative treatments for various diseases, with a particular emphasis on autoimmune diseases and cancer. Its primary products include HANLIKANG, a rituximab injection for conditions like Non-Hodgkin’s lymphoma and rheumatoid arthritis, and HLX79, a human sialidase fusion protein.
YTD Price Performance: 33.33%
Average Trading Volume: 1,434,294
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.17B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.